Ignite Creation Date:
2024-05-06 @ 5:00 PM
Last Modification Date:
2024-10-26 @ 2:20 PM
Study NCT ID:
NCT05159908
Status:
COMPLETED
Last Update Posted:
2023-09-21
First Post:
2021-11-30
Brief Title:
A Study to Investigate How Effective Safe and Tolerable the Drug NBI-921352 is When Used With Anti-seizure Medications in Adults With Focal Onset Seizures
Sponsor:
Neurocrine Biosciences
Organization:
Neurocrine Biosciences
Study Overview
Official Title:
A Phase 2 Randomized Double-Blind Placebo-Controlled Dose-Finding Study to Investigate Safety Tolerability Pharmacokinetics and Efficacy of NBI-921352 as Adjunctive Therapy in Adult Subjects With Focal Onset Seizures FOS
Status:
COMPLETED
Status Verified Date:
2024-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study will evaluate the safety pharmacokinetics and efficacy of three different doses of NBI-921352 versus placebo in adults with focal onset seizures
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2021-001433-39 | EUDRACT_NUMBER | None | None |